We advised MedTech startup BrachyDOSE on attracting over EUR 0.5 million in investment. The funds will be used to advance the development of the company’s innovative device for cancer patients.
The lead investor in this round was the venture capital fund Coinvest Capital, which contributed EUR 0.3 million. Other investors included the fund BSV Ventures and the business angel networks LitBAN and EstBAN.
Innovative technology in oncology
Neringa Šeperienė, founder of BrachyDOSE, says the team is addressing one of the most pressing challenges in cancer treatment – the side effects of radiotherapy. “It’s crucial that hospitals and doctors will be able to significantly improve the quality of cancer treatment. In some cases, this technology may help eliminate up to 100% of radiotherapy-induced side effects”, – Šeperienė comments.
The investment raised in this round will be used to test the startup’s innovative radiation dose measurement system in a real hospital environment and to obtain CE/MDR certification.
>CE certification signifies that, following an assessment by the manufacturer or a notified body, the product meets the European Union’s (EU) safety, health, and environmental protection standards. Any product sold in the EU, regardless of where it is manufactured, must carry the CE mark.
Once certified, the product can be implemented in hospitals across the EU.
Our team and services
Our team, consisting of senior associate Mindaugas Baniulis and associates – Goda Jakubauskaitė and Airida Buzaitė – advised the startup on all investment-related matters, including representation during negotiations with investors and the preparation of all investment documentation.
